gatifloxacin has been researched along with Infections, Soft Tissue in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 9.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 5.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| "Gatifloxacin was active at | 1.30 | Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. ( Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, K; Warren, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldstein, EJ | 1 |
| Citron, DM | 1 |
| Merriam, CV | 1 |
| Tyrrell, K | 1 |
| Warren, Y | 1 |
| Tarshis, GA | 1 |
| Miskin, BM | 1 |
| Jones, TM | 1 |
| Champlin, J | 1 |
| Wingert, KJ | 1 |
| Breen, JD | 1 |
| Brown, MJ | 1 |
1 trial available for gatifloxacin and Infections, Soft Tissue
| Article | Year |
|---|---|
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Admi | 2001 |
1 other study available for gatifloxacin and Infections, Soft Tissue
| Article | Year |
|---|---|
Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
Topics: Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Fluoroquinolones; G | 1999 |